Targets › SRD5A1
4 programs from 4 companies in 19 trials: 15 Phase 2, 3 Phase 3, 1 Phase 4; Oncology; next expected readout Nov 2026.
Catalyzes the irreversible stereospecific reduction of the delta 4,5 bond (double bond between carbons 4 and 5) of various 3-oxo steroids (3-keto steroids) producing their 5alpha dihydro-3-oxo forms. Converts testosterone into 5-alpha-dihydrotestosterone (DHT), a more potent androgen as it is the preferred ligand for androgen receptor (AR) transactivation, making this reaction a key step in male sexual…. (UniProt, P18405)
Open in Phaseline: the race on SRD5A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Turku University Hospital | Dutasteride Steroid 5-alpha-reductase inhibitor | SRD5A1, SRD5A2, SRD5A3 | Phase 4 | Prostatic Hyperplasia | Dec 2026 |
| Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Abiraterone Cytochrome P450 17A1 inhibitor; Androgen Receptor antagonist; Steroid 5-alpha-reductase inhibitor | CYP17A1, AR, SRD5A1, SRD5A2, SRD5A3 | Phase 2 | Prostate Cancer; Metastatic Castration-resistant Prostate Cancer (mCRPC); Castration Levels of Testosterone; Advanced Prostate Adenocarcinoma … | Nov 2026 |
| Radboud University Medical Center | Dutasteride Steroid 5-alpha-reductase inhibitor | SRD5A1, SRD5A2, SRD5A3 | Phase 2 | Salivary Duct Carcinoma | Sep 2027 |
| Paul Toren | Dutasteride Steroid 5-alpha-reductase inhibitor | SRD5A1, SRD5A2, SRD5A3 | Phase 2 | Bladder Cancer | Apr 2030 |
Prostate Cancer (6) Metastatic Prostate Cancer (2) Prostatic Hyperplasia (1) Bladder Cancer (1) Metastatic Castration-resistant Prostate Cancer (mCRPC) (1) Castration Levels of Testosterone (1) Advanced Prostate Adenocarcinoma (1) Prostate Cancer (Diagnosis) (1) Metastatic Castration-resistant Prostate Cancer (1) Prostate Cancer Metastatic Disease (1) Salivary Gland Carcinoma (1) Prostate Carcinoma (1)
small molecule (4)
Turku University Hospital (1) Paul Toren (1) Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair (1) Radboud University Medical Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.